FDA 483 - Virbac Corporation - January 22, 2026

Virbac Corporation, an animal drug manufacturer in Bridgeton, MO, was cited for significant deficiencies during an FDA inspection. Observations included failure to submit timely field alert reports for microbiological excursions, inadequate identity testing of raw materials, and a lack of scientific rationale for microbiological specifications in finished products. These issues indicate potential risks to product quality and patient safety.